Adial Pharmaceuticals (NASDAQ:ADIL) announces that the holder of the sole remaining, outstanding convertible note has fully converted the balance of the note into common shares of the Company.
As previously reported, the convertible note had a face value of $325,000 and was convertible into 162,500 shares of common stock.
Shares are down 9% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.